Type I lamellar ichthyosis improved by tazarotene 0.1% gel.
The efficacy of tazarotene 0.1% gel in a 30-year-old woman with type I lamellar ichthyosis is reported. The drug was applied to 15% of the total body surface area as follows: once daily for 2 weeks, three times a week for further 2 weeks, followed by a once weekly maintenance application. During the first week of treatment there was partial improvement obtained and in the next 14 days further reduction of scaling within the tazarotene-treated areas was observed. After 4 months of maintenance application, there was a marked overall improvement in the treated areas. Side-effects consisted only of mild pruritus, slight burning and irritation. In essence, the therapeutic benefit obtained was comparable with that of systemic retinoids but without the adverse systemic side-effects. As noted in other reports, tazarotene 0.1% gel seems to be a valuable and safe therapeutic option for this severe genodermatosis.
Marulli
G C
GC
Department of Dermatology, Tor Vergata University of Rome, Rome, Italy.
Campione
E
E
Chimenti
M S
MS
Terrinoni
A
A
Melino
G
G
Bianchi
L
L
D000287:Administration, Topical; D000328:Adult; D003879:Dermatologic Agents / Q000008:administration & dosage*; D005260:Female; D005782:Gels; D006801:Humans; D007057:Ichthyosis / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D009539:Nicotinic Acids / Q000008:administration & dosage*; D016896:Treatment Outcome; D012176:Retinoids
D003879:Dermatologic Agents; D005782:Gels; D009539:Nicotinic Acids; C086827:tazarotene; D012176:Retinoids